Pregnant women who gain excessive or even appropriate weight, according to current guidelines, are four times more likely than women who gain inadequate weight to have a baby who becomes overweight in early childhood.
The Food and Drug Administration (FDA) notified Hill’s Pet Nutrition, Inc., of Topeka, Kansas, that FDA testing has detected melamine and melamine byproducts in wheat gluten received by the company to make dry cat food.
The BMA is launching updated guidance on withholding and withdrawing life-prolonging treatment, to take into account the major changes for patients and doctors that will come into force when the Mental Capacity Act is implemented in England and Wales in April and October 2007.
A new study suggests that people whose diets contain dramatically more of one kind of polyunsaturated fatty acid than another may be at greater risk for both clinical depression and certain inflammatory diseases.
Soldiers exposed to the deafening din of battle have little defense against hearing loss, and are often reluctant to wear protective gear like ear plugs that could make them less able to react to danger. But what if a nutritious daily “candy bar” could prevent much of that potential damage to their hearing?
A consultation to explore ways of reducing the average amount of saturated fat in people?s diets and help make healthier eating easier has been published today by the Food Standards Agency.
High consumption of trans fat, found mainly in partially hydrogenated vegetable oils and widely used by the food industry, has been linked to an increased risk of coronary heart disease (CHD).
People purchase foods based on their income level, their belief in a food?s health benefit and cost. However, ethnicity and gender also impact people?s food choices, according to researchers at the Johns Hopkins Bloomberg School of Public Health.
A recent study noted that overweight and obese people who went on a low carb diet lost more weight than their peers who went on a low-fat, portion-controlled diet.
Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending the approval of REMICADE(R) (infliximab) for the treatment of severe, active Crohn’s disease (CD) in pediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy, or who are intolerant to, or have contraindications for, such therapies.